Sino Biopharmaceutical (HKG:1177) has approved a plan to spend up to HK$2 billion over the next 12 months on share repurchases in the open market, according to a filing with the Hong Kong Exchange on Monday.

The approved amount may be used for shares repurchased directly by the biotech firm as well as shares acquired by the trustee administering its restricted share award scheme.

Since the start of 2026, the company has spent about HK$338 million to acquire 60.35 million shares under its repurchase program.